Clinical trial
Equfina Tablet 50 mg Post Marketing Surveillance Protocol
NCT05225324 is registered in ClinicalTrials.gov with Eisai Korea Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Equfina Tablet 50 mg Post Marketing Surveillance Protocol
- Lead sponsor
- Eisai Korea Inc.
- Phase
- Observational
- Overall status
- Completed
- Start date
- June 3, 2021
- Completion date
- March 20, 2025
- Enrollment
- 702 (actual)
- Sites
- 27
Conditions
As the registry lists them; a condition with its own page is linked.